A study investigating the results of ElleVet Sciences CBD+CBDA oil and its efficacy on dogs with seizures was completed and results show success. Analysis of the data show that 40% of the dogs enrolled in the study had a reduction in severity and frequency of seizures. The paper is published in Frontiers of Veterinary Medicine.
While CBD has been believed to have potential as an option for seizures in dogs, there have been few studies on the topic prior to this study showing efficacy in dogs.
The research team, led by Dr. Gabriel Garcia of the University of Florida Veterinary School, conducted a 2 yearlong study examining a 3 month-long treatment in a placebo blinded controlled clinical trial where dogs were either given a placebo or ElleVet Sciences CBD+CBDA oil. When compared to the placebo group, the frequency and severity of seizures dropped significantly for 40% of dogs on the ElleVet oil. All dogs enrolled were on concurrent seizure products with no adverse events occurring.
Chief medical officer of ElleVet Sciences, Dr. Joe Wakshlag stated, "This can be a regimen that is safe and effective and is a worthwhile addition to the current regimen for refractory seizures when commonly used products are not working as well as intended. This study has similar success to what is observed in people, and I am extremely pleased to be able to share the results with the veterinary community."
ElleVet Sciences co-founder Amanda Howland, stated, "It is not surprising to us that there were positive results as CBD has been used in the human realm for some time. What was surprising was the low dose that is needed of our full spectrum product compared to CBD isolate used in human studies."
Photo by Ryan Lange on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.